Sarepta bags drug to fully unlock DMD gene therapy opportunity

Sarepta Therapeutics has secured a license to a drug that could enable more patients to receive its gene therapies. The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy (LGMD) patients.